Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 202-209

  Bernardi, Stella ^a,b   Zennaro, Cristina ^c   Palmisano, Silvia ^d   Velkoska, Elena ^e   Sabato, Nicoletta ^f   Toffoli, Barbara ^g   Giacomel, Greta ^d   Buri, Luigi ^d   Zanconati, Fabrizio ^d   Bellini, Giuseppe ^f   Burrell, Louise M ^e   De Manzini, Nicolò ^d   Fabris, Bruno ^f  

^a UNIVERSITY OF FERRARA   (Italy)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF TRIESTE   (Italy)

^g IRCCS Burlo Garofalo   (Italy)

Author keywords

angiotensin 1 7; Angiotensin converting enzyme 2; cell cycle; cell lines; colon adenocarcinoma; Mas receptor; oncogene; renin angiotensin system

Indexed keywords

ANGIOTENSIN 1-7; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; MAS RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION;

ADENOCARCINOMA; AGED; ANGIOTENSIN I; ANGIOTENSIN II; CACO-2 CELLS; CELL CYCLE; COLONIC NEOPLASMS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84859993289     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311426023     Document Type: Article

References (22)

1. Raizada MK and Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 2007; 50: 112-119. (Pubitemid 47267736)
2. Freeman EJ, Chisolm GM, Ferrario CM and Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104-108. (Pubitemid 26231097)
3. Tallant EA, Diz DI and Ferrario CM. State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 1999; 34: 950-957.
4. Tallant EA and Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 2003; 42: 574-579. (Pubitemid 37237356)
5. Gallagher PE and Tallant EA. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004; 25: 2045-2052. (Pubitemid 39534840)
6. Menon J, Soto-Pantoja DR, Callahan MF, et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007; 67: 2809-2815. (Pubitemid 46548970)
7. Soto-Pantoja DR, Menon J, Gallagher PE and Tallant EA. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther 2009; 8: 1676-1683.
8. Neo JH, Ager EI, Angus PW, Zhu J, Herath CB and Christophi C. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 10: 134.
9. Santos RA, Krieger EM and Greene LJ. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 1985; 7: 244-252. (Pubitemid 15093650)
10. Herath CB, Warner FJ, Lubel JS, et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 2007; 47: 387-395. (Pubitemid 47176156)
11. Barton M, Carmona R, Morawietz H, et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000; 35: 329-336. (Pubitemid 30054195)
12. Burrell LM, Risvanis J, Kubota E, et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-375; discussion 322-364.
13. Burchill L, Velkoska E, Dean RG, et al. Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression. Exp Physiol 2008; 93: 622-630. (Pubitemid 351595052)
14. Velkoska E, Dean RG, Griggs K, Burchill L and Burrell LM. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci (Lond) 2011; 120: 335-345.
15. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888-897.
16. Talero E, Sanchez-Fidalgo S, Villegas I, de la Lastra CA, Illanes M and Motilva V. Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis. Inflamm Bowel Dis 2011; 17: 696-710.
17. Fasano O, Birnbaum D, Edlund L, Fogh J and Wigler M. New human transforming genes detected by a tumorigenicity assay. Mol Cell Biol 1984; 4: 1695-1705. (Pubitemid 14008277)
18. Young D, Waitches G, Birchmeier C, Fasano O and Wigler M. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell 1986; 45: 711-719. (Pubitemid 16063134)
19. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-511. (Pubitemid 351185806)
20. Rodgers K, Xiong S, Felix J, et al. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen 2001; 9: 238-247. (Pubitemid 32706271)
21. Ellefson DD, diZerega GS, Espinoza T, Roda N, Maldonado S and Rodgers KE. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. Cancer Chemother Pharmacol 2004; 53: 15-24. (Pubitemid 38161184)
22. Alenina N, Xu P, Rentzsch B, Patkin EL and Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008; 93: 528-537. (Pubitemid 351595044)